Tg Therapeutics, Inc.
A biopharmaceutical company focused on B-cell-driven diseases, most notably multiple sclerosis. Its main product, BRIUMVI (ublituximab), is an infusion approved by the US FDA in 2022 to treat relapsing forms of MS. The firm traces roots to 1993 but took the TG Therapeutics name around 2012 under biotech veteran Michael Weiss, and the "TG" initials are commonly tied to its founders.
Granted 2.37M
Granted 252.5K · Sold 69.2K
Granted 57.0K
Granted 57.0K · Sold 35.0K
Granted 57.0K
Granted 63.7K · Sold 64.5K
Granted 57.0K · Sold 56.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Weiss Michael SCEO, Director · 5 transactions | -19% | 9.78M | 2.37M | — | — |
| Power Sean ACFO · 7 transactions | +21.9% | 798.1K | 252.5K | — | 69.2K |
| Hoberman KennethDirector · 3 transactions | +25.6% | 279.7Kas of Jun 2025 | 57.0K | — | — |
| Echelard YannDirector · 6 transactions | +10.9% | 223.8K | 57.0K | — | 35.0K |
| Hume DanielDirector · 4 transactions | -2.8% | 192.7Kas of Jun 2025 | 57.0K | — | — |
| Charney Laurence NDirector · 10 transactions | -23.4% | 179.7K | 63.7K | — | 64.5K |
| Lonial SagarDirector · 8 transactions | +0.2% | 94.1K | 57.0K | — | 56.8K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -225.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.